» Articles » PMID: 18442053

PRIMA-1 Synergizes with Adriamycin to Induce Cell Death in Non-small Cell Lung Cancer Cells

Overview
Journal J Cell Biochem
Date 2008 Apr 30
PMID 18442053
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

p53-dependent apoptosis is important for the efficacy of cancer treatment, and tumors carrying mutant p53 are often resistant to chemotherapy. Non-small cell lung cancer (NSCLC) cells generally exhibit resistance to apoptosis following treatment with many cytotoxic drugs. The new molecule PRIMA-1 appears to kill human tumor cells by restoring the transcriptional activity to mutated p53. We investigated the induction of apoptosis in response to this drug in three NSCLC cell lines carrying different p53 proteins: A549 (p53wt), LX1 (p53R273H), and SKMes1 (p53R280K). PRIMA-1 alone did not trigger apoptosis but significantly reduced cell viability. However, in combination with adriamycin, PRIMA-1 strengthen the adriamycin-induced apoptosis in A549 and LX1. Interestingly, even in SKMes1 cells, the combined treatment triggered a strong PARP cleavage without DNA fragmentation. Our data suggest that in NSCLC cells, PRIMA-1 may induce cell death through pathways other than apoptosis but may synergize with adriamycin to trigger an apoptotic response.

Citing Articles

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer.

Zhang S, Carlsen L, Hernandez Borrero L, Seyhan A, Tian X, El-Deiry W Biomolecules. 2022; 12(4).

PMID: 35454137 PMC: 9029346. DOI: 10.3390/biom12040548.


Should mutant TP53 be targeted for cancer therapy?.

Wang Z, Strasser A, Kelly G Cell Death Differ. 2022; 29(5):911-920.

PMID: 35332311 PMC: 9091235. DOI: 10.1038/s41418-022-00962-9.


Antitumor Effects of PRIMA-1 and PRIMA-1 (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?.

Menichini P, Monti P, Speciale A, Cutrona G, Matis S, Fais F Cells. 2021; 10(1).

PMID: 33430525 PMC: 7827888. DOI: 10.3390/cells10010098.


PRIMA-1 and PRIMA-1 (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.

Perdrix A, Najem A, Saussez S, Awada A, Journe F, Ghanem G Cancers (Basel). 2017; 9(12).

PMID: 29258181 PMC: 5742820. DOI: 10.3390/cancers9120172.


Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR.

Richer A, Friel J, Carson V, Inge L, Whitsett T Pharmgenomics Pers Med. 2015; 8:63-79.

PMID: 25897257 PMC: 4397718. DOI: 10.2147/PGPM.S52845.